No Difference in Cisplatin/Etoposide, Carboplatin/Etoposide in Lung Cancer

Share this content:

the Cancer Therapy Advisor take:

Researchers sought to determine the differences in overall survival and locoregional control rates in patients treated with cisplatin and etoposide versus patients treated with carboplatin and etoposide.

Study participants were patients with small cell lung cancer who had both limited and extensive disease. All patients included in the study were diagnosed with small cell lung cancer between January 2004 and December 2008. There were 249 patients with limited disease small cell lung cancer and 287 patients with extensive disease small cell lung cancer.

The patients who received cisplatin and etoposide were older in both the limited disease group (median 62 vs. 72, P<0.001) and the extensive disease group (median 62 vs. 73, P<0.001). The median time to follow-up was 22 months for extensive disease and 37 months for limited disease and the overall survival was 18 months and 23 months, respectively (P=0.10).

Rates of locoregional control at the 12 month mark were 68% for patients treating with carboplatin and etoposide and 81% for patients treated with cisplatin and etoposide (P=0.97). The median overall survival for patients with extensive disease small cell lung cancer was 10 months in patients receiving carboplatin and etoposide and 11 months in patients receiving cisplatin and etoposide (P=0.24).

Overall the researchers concluded that there was no significant difference in patients who were treated with either treatment option, even when considering the age of the patient or the stage of their disease. 

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC
No significant difference in patients who were treated with either treatment option in SCLC.
This descriptive study compares overall survival (OS) and locoregional control (LRC) rates between cisplatin-etoposide (EP) and carboplatin-etoposide (EC) at a population level in patients with limited disease (LD) and extensive disease (ED) small cell lung cancer (SCLC).
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters